Blog

The latest thoughts from Medicines Law & Policy partners.

Legal tools that lower medicines prices have expanded access to medicines for over two...

LONDON, UK: Millions of people are priced out of access to life-saving medicines. Use of legal tools to reduce prices has been under-reported and...

The Waiver that Wasn’t: Is the pharma lobby responsible?

Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...

Decision on intellectual property waiver over Covid technology on hold till 2021; what are...

Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer. The...

MSF’s Access Campaign is an invaluable actor in global health; shutting it down is...

On 20 June, STAT News reported that Médecins Sans Frontières (MSF) is closing down their Access Campaign, effective as of 31 December 2024. It...

Vaccine knowledge needs to be a global public good: Remarks to the World Trade...

Ellen ‘t Hoen, Medicines Law & Policy, at the World Trade Organization-World Health Organization High-Level Dialogue on Expanding COVID-19 Vaccine Manufacturing to Promote Equitable...

Medicines Law & Policy welcomes WHO’s Solidarity Call to Action to realise equitable global...

The World Health Organization today with Costa Rica launched the "COVID-19 Technology Access Pool (C-TAP)" to ensure that knowledge, data and intellectual property are...

Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...

On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...

Wrapping up 2019 – Noteworthy Medicines Law and Policy Events

2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....

Cystic Fibrosis Medicines Wars in Europe

Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...

Commission report on competition enforcement in the pharmaceutical sector

Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...